PH25859A - Composition for treatment of ischemic disorder - Google Patents

Composition for treatment of ischemic disorder

Info

Publication number
PH25859A
PH25859A PH38013A PH38013A PH25859A PH 25859 A PH25859 A PH 25859A PH 38013 A PH38013 A PH 38013A PH 38013 A PH38013 A PH 38013A PH 25859 A PH25859 A PH 25859A
Authority
PH
Philippines
Prior art keywords
treatment
composition
ischemic disorder
ischemic
disorder
Prior art date
Application number
PH38013A
Other languages
English (en)
Inventor
Norio Shinmamoto
Kazumi Ogata
Original Assignee
Takeda Chemical Industries Ltd
Senju Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd, Senju Pharma Co filed Critical Takeda Chemical Industries Ltd
Publication of PH25859A publication Critical patent/PH25859A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH38013A 1988-01-11 1989-01-06 Composition for treatment of ischemic disorder PH25859A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP448088 1988-01-11

Publications (1)

Publication Number Publication Date
PH25859A true PH25859A (en) 1991-12-02

Family

ID=11585270

Family Applications (1)

Application Number Title Priority Date Filing Date
PH38013A PH25859A (en) 1988-01-11 1989-01-06 Composition for treatment of ischemic disorder

Country Status (7)

Country Link
US (1) US4948786A (de)
EP (1) EP0324387B1 (de)
KR (1) KR0125931B1 (de)
AT (1) ATE103812T1 (de)
CA (1) CA1328810C (de)
DE (1) DE68914292T2 (de)
PH (1) PH25859A (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2854631B2 (ja) * 1989-11-21 1999-02-03 千寿製薬株式会社 糖尿病合併症および老化によって引き起こされる疾患の予防・治療剤
GR1002610B (el) * 1991-01-02 1997-02-20 Johnson & Johnson Consumer Products Inc. Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ.
TW262386B (de) * 1992-09-30 1995-11-11 Senju Pharma Co
TW252918B (de) * 1993-03-31 1995-08-01 Senju Pharma Co
CA2129509A1 (en) * 1993-09-10 1995-03-11 Kazumi Ogata Pharmaceutical composition for renal disorder and a dialysis solution for extracorporeal hemodialysis
JPH07196516A (ja) * 1993-12-29 1995-08-01 Senju Pharmaceut Co Ltd 痔疾患治療剤
JPH07215801A (ja) * 1994-01-28 1995-08-15 Senju Pharmaceut Co Ltd 肺保存剤および肺保存方法
JPH07330501A (ja) * 1994-06-14 1995-12-19 Senju Pharmaceut Co Ltd 肝保存剤および肝保存方法
CA2152693A1 (en) 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
CA2179940A1 (en) * 1995-07-18 1997-01-19 Kazumi Ogata Antiallergic composition comprising a phosphoric diester compound
CA2186654A1 (en) * 1995-10-13 1997-04-14 Masayuki Nakamura Phosphoric diester
JPH09194375A (ja) * 1996-01-17 1997-07-29 Senju Pharmaceut Co Ltd 免疫抑制作用増強剤
WO1999039716A1 (en) * 1998-02-03 1999-08-12 Senju Pharmaceutical Co., Ltd. Preventives and remedies for neuron digeneration-associated diseaseas
CA2335361A1 (en) 1998-06-19 1999-12-23 Senju Pharmaceutical Co., Ltd. Medicament for reducing side effects of adrenocortical hormones
WO2002026238A1 (en) * 2000-09-26 2002-04-04 Vital Health Sciences Pty Ltd. Phosphate derivative supplements
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
AU2002317053B2 (en) 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
BRPI0406484A (pt) * 2003-01-17 2005-12-06 Vital Health Sciences Pty Ltd Método de inibição da ocorrência de uma ou mais das seguintes condições: a proliferação de monócitos/macrófagos; ou a proliferação de células do músculo liso; ou a expressão de receptores de cd36; ou a absorção de lipoproteìna de baixa densidade - ldl oxidada, método de alìvio de sintomas de tratamento ou prevenção de aterosclerose; de diabetes; do mal de alzheimer, método de inibição da ocorrência da formação de placas no sistema vascular, método de alìvio da inflamação associada a ocorrência de uma ou de mais das seguintes condições: a proliferação de monócitos, a proliferação de células do músculo liso, a expressão de ldl oxidadas ou de receptor descontaminante, composição farmacêutica, uso de uma quantidade eficaz de um ou mais derivados ou fosfato de um ou mais agentes de transferência de elétrons conjuntamente com um veìculo ou um diluente apropriado, uso de uma quantidade eficaz de um ou mais derivados de fosfato de (alfa)-tocoferol conjuntamente com um veìculo ou um diluente apropriado e uso de uma quantidade eficaz de um ou mais derivados de fosfato de um ou mais agentes de transferência de elétrons selecionados do grupo que consiste em fosfato mono-tocoferila, fosfato de di-tocoferila e as misturas destes conjuntamente com um veìculo ou um diluente apropriado
CA2557354C (en) 2004-03-03 2013-05-07 Vital Health Sciences Pty Ltd. Alkaloid formulations
MX2007015949A (es) 2005-06-17 2008-03-07 Vital Health Sciences Pty Ltd Un vehiculo que comprende uno o mas derivados de fosfato de di- y/o mono-(agentes de transferencia de electrones) o complejos de los mismos.
US10071030B2 (en) 2010-02-05 2018-09-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
JP5806287B2 (ja) 2010-03-30 2015-11-10 フォスファジェニクス リミティド 経皮送達パッチ
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
WO2014129519A1 (en) 2013-02-20 2014-08-28 Semiconductor Energy Laboratory Co., Ltd. Peeling method, semiconductor device, and peeling apparatus
KR102334815B1 (ko) 2014-02-19 2021-12-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치 및 박리 방법
MX383940B (es) 2015-12-09 2025-03-14 Phosphagenics Ltd Formulación farmacéutica que contiene tocol fosfato.
JP7198754B2 (ja) 2016-12-21 2023-01-04 アベーチョ バイオテクノロジー リミテッド 方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59219295A (ja) * 1983-05-30 1984-12-10 Senjiyu Seiyaku Kk リン酸ジエステルまたはその塩およびそれらの製造法
DE3682538D1 (de) * 1985-05-15 1992-01-02 Roshdy Ismail Vitamin e-haltiges mittel zur verbesserung der eigenschaften des blutes.
ZA852614B (en) * 1985-05-17 1986-10-09 Takeda Chemical Industries, Ltd. Ascorbic acid ethers and their production
JPS62205091A (ja) * 1986-03-04 1987-09-09 Senjiyu Seiyaku Kk 新規なリン酸ジエステルならびにその塩、その製造法およびそれを含有する製剤
JP2526059B2 (ja) * 1987-04-28 1996-08-21 千寿製薬株式会社 抗潰瘍剤

Also Published As

Publication number Publication date
DE68914292D1 (de) 1994-05-11
US4948786A (en) 1990-08-14
EP0324387A3 (en) 1990-06-13
KR0125931B1 (ko) 1997-12-26
ATE103812T1 (de) 1994-04-15
EP0324387B1 (de) 1994-04-06
DE68914292T2 (de) 1995-09-28
EP0324387A2 (de) 1989-07-19
KR890011592A (ko) 1989-08-21
CA1328810C (en) 1994-04-26

Similar Documents

Publication Publication Date Title
EP0324387A3 (en) Composition for treatment of ischemic disorder in organs
FI890689A0 (fi) 3-alkenyl-1-azabicyklo-/3.2.0/ -hept-2-en-2-karboxylsyrafoereningar.
GB8900382D0 (en) 2-aminopyrimidinone derivatives
PH23607A (en) Amide derivatives and pharmaceutical composition containing said compounds
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
ZA896067B (en) Chemical compounds
PL309874A1 (en) Novel derivatives of pyrrolocarbasol, method of obtaining them and pharmaceutical composition containing such derivatives
EP0228845A3 (en) N-containing heterocyclic compounds, processes for the preparation thereof and composition comprising the same
DE3362504D1 (en) 1-carboxyalkanoylindoline-2-carboxylic-acid esters, their preparation, pharmaceutical compositions containing them, and their therapeutic use
MY105538A (en) Derivatives of thieno-triazolo-diazepine, a preparation process of the same and therapeutic compositions containing them.
ES2046641T3 (es) Composicion antitumoral.
ZA892695B (en) 2-alkyl-3-benzoylbenzofurans and pharmaceutical compositions containing them
DE69001722D1 (de) Entzuendungshemmende und/oder antiallergische zusammensetzung, die glutathionderivate enthaelt.
PT91607A (pt) Process for the preparation of substituted beta-diketones and of pharmaceutical compositions containing them
IL85768A0 (en) Benzoxazine derivatives,their preparation and pharmaceutical compositions containing them
ZA912618B (en) 3-aminochroman derivatives,process for preparing these and pharmaceutical compositions containing them
HUT75647A (en) Imidazolidinone derivatives and pharmaceutical compositions containing them, which are suitable for treament of senile dementia
HUT49283A (en) Process for production of medical compositions applicable for treatment of peptical ulcer
GR3003126T3 (en) Quinolinecarboxylic acid derivatives, a composition comprising the same, process for preparing the same, and the use of the same for the manufacture of medicaments
GR3007219T3 (de)
PT91613A (pt) Process for the preparation of antihypertensive 3-piperidinyl-indazole derivatives
HUT44268A (en) Process for preparing compounds with construction similar to antibiotic tan-749
EP0292981A3 (en) 2-selenomethyl-1, 4-dihydropyridines a process for the preparation thereof and pharmaceutical compositions containing them
ATE97902T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung.